Premium
Efficacy and safety of risankizumab in psoriasis patients who failed anti‐IL ‐17, anti‐12/23 and/or anti IL ‐23: Preliminary data of a real‐life 16‐week retrospective study
Author(s) -
Megna Matteo,
Fabbrocini Gabriella,
Ruggiero Angelo,
Cinelli Eleonora
Publication year - 2020
Publication title -
dermatologic therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.595
H-Index - 68
eISSN - 1529-8019
pISSN - 1396-0296
DOI - 10.1111/dth.14144
Subject(s) - medicine , tolerability , ustekinumab , interleukin 23 , gastroenterology , interleukin 17 , dermatology , adverse effect , disease , cytokine , infliximab
Up until now, real‐life experiences on the efficacy of risankizumab in patients who had previously failed anti‐IL17, anti‐IL12/23 or anti‐IL23 inhibitor are not reported. We carried out a single‐center, retrospective study, to evaluate the efficacy, safety and tolerability of patients under risankizumab who previously failed anti‐IL17, anti‐IL12/23, or anti‐IL23 inhibitors in a real‐life setting. A total of eight patients were enrolled (four men and four women, mean age 45.8 ± 14.3 years). Five of them (62.5%) had received ustekinumab, seven (87.5%) at least one anti‐IL17, and only one (12.5%) patient guselkumab. Secukinumab had been used in five (62.5%) cases, and ixekizumab in four (50.0%). Baseline mean PASI and BSA were 11.9 ± 5.5, and 22.9 ± 13.1, respectively, and 3.3 ± 1.7 and 7.5 ± 5 ( P < .001 and P < .01) at week 16. Mean baseline NAPSI (18.0 ± 8.5) reduced to 7 ± 1.4 at week 16. Palmo‐plantar and scalp area showed a reduction of 67.5% and 99.9% at week 16, respectively. No AEs was reported. Real‐life preliminary data show risankizumab as a promising therapeutic option in patients who failed anti‐IL‐17, anti‐IL12/23 and even the other anti‐IL‐23 counterpart, guselkumab.